What is the treatment for pulmonary embolism?

The main treatment for pulmonary embolism is anticoagulation.
Heparin is the only drug that achieves a rapid effect and is used initially.
Low molecular weight heparins have the advantage of being dosed according to the patient's weight and can be administered subcutaneously.
In cases of morbid obesity, renal insufficiency or pregnancy, anti-factor X activity should be measured.
The use of new oral drugs such as dabigatran and rivaroxaban is recommended.
Fibrinolysis is indicated in cases of massive pulmonary embolism with right ventricular dysfunction.
The decision to administer fibrinolysis with heparin is individual and depends on the risk-benefit balance.
Dabigatran is an oral direct thrombin inhibitor that does not require monitoring and has a predictable anticoagulant effect.
Rivaroxaban is a potent and selective oral inhibitor of activated factor X that has been shown to be effective in preventing recurrent thromboembolic events.
Apixaban is another factor Xa inhibitor that has shown promising results in clinical trials.